GBLX - Gb Sciences initiates new preclinical studies through Canadian subsidiary

Gb Sciences (OTCQB:GBLX) has initiated new preclinical studies at the National Research Council of Canada (NRC) through its Canadian subsidiary GbS Global Biopharma. The NRC will test GbS' proprietary, psychotropic plant-based formulas for the treatment of depression and anxiety. GbS has leveraged its patent-pending PhAROS (Phytomedical Analytics for Research Optimization at Scale) platform to identify these combinations of plant compounds for novel drug candidates to treat depression and anxiety. The PhAROS platform is a revolutionary, AI-driven science gateway and virtual research environment for drug discovery.

For further details see:

Gb Sciences initiates new preclinical studies through Canadian subsidiary